Abstract
Background: In patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI), dual antiplatelet therapy has been shown to effectively prevent stent thrombosis and other ischemic cardiovascular events. The frequent occurrence of atrial fibrillation (AF) and concomitant CAD in the same individuals, suggests that clinicians will encounter many patients treated with PCI who will require anticoagulant treatment for the prevention of the thromboembolic complications of AF.
Methods: In this narrative review we provide an overview and update of evidence regarding antiplatelet therapy in patients with AF undergoing PCI.
Results: The combination of dual antiplatelet therapy with anticoagulants may further protect a patient from ischemic complications, at the cost, however, of a several-fold increased bleeding risk. The introduction of novel pharmaceutical agents in both categories implies that there is paucity of data regarding the efficacy and, more importantly, the safety of between-drug combinations.
Conclusion: Careful consideration of the patient’s individual characteristics and assessment of the risk for bleeding and thrombotic events using validated risk prediction tools is of great importance in order to maximize the benefits for each patient, while minimizing the risk for hemorrhage.
Keywords: Atrial fibrillation, percutaneous coronary intervention, antiplatelet thepary.
Current Pharmaceutical Design
Title:Selection of Antithrombotic Therapy in Patients with Atrial Fibrillation and Percutaneous Coronary Intervention
Volume: 22 Issue: 29
Author(s): Theodoros A. Zografos and Demosthenes G. Katritsis
Affiliation:
Keywords: Atrial fibrillation, percutaneous coronary intervention, antiplatelet thepary.
Abstract: Background: In patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI), dual antiplatelet therapy has been shown to effectively prevent stent thrombosis and other ischemic cardiovascular events. The frequent occurrence of atrial fibrillation (AF) and concomitant CAD in the same individuals, suggests that clinicians will encounter many patients treated with PCI who will require anticoagulant treatment for the prevention of the thromboembolic complications of AF.
Methods: In this narrative review we provide an overview and update of evidence regarding antiplatelet therapy in patients with AF undergoing PCI.
Results: The combination of dual antiplatelet therapy with anticoagulants may further protect a patient from ischemic complications, at the cost, however, of a several-fold increased bleeding risk. The introduction of novel pharmaceutical agents in both categories implies that there is paucity of data regarding the efficacy and, more importantly, the safety of between-drug combinations.
Conclusion: Careful consideration of the patient’s individual characteristics and assessment of the risk for bleeding and thrombotic events using validated risk prediction tools is of great importance in order to maximize the benefits for each patient, while minimizing the risk for hemorrhage.
Export Options
About this article
Cite this article as:
Zografos A. Theodoros and Katritsis G. Demosthenes, Selection of Antithrombotic Therapy in Patients with Atrial Fibrillation and Percutaneous Coronary Intervention, Current Pharmaceutical Design 2016; 22 (29) . https://dx.doi.org/10.2174/1381612822666160623070130
DOI https://dx.doi.org/10.2174/1381612822666160623070130 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Noninvasive Vascular Strain Imaging: from Methods to Application
Current Medical Imaging Anticoagulation in Patients with Heart Failure
Cardiovascular & Hematological Agents in Medicinal Chemistry Prevention of Ischemic Stroke: Antithrombotic Therapy in Cardiac Embolism
Current Drug Targets Differential Effects of Trans and Polyunsaturated Fatty Acids on Ischemia/ Reperfusion Injury and its Associated Cardiovascular Disease States
Current Pharmaceutical Design Cancer Therapeutics-Related Cardiovascular Complications. Mechanisms, Diagnosis and Treatment
Current Pharmaceutical Design Loading of Propranolol Hydrochloride on MCF and Sustained Release
Micro and Nanosystems Lifestyle Choices and Endothelial Function: Risk and Relevance
Current Vascular Pharmacology Advanced Echocardiographic Imaging of the Congenitally Malformed Heart
Current Cardiology Reviews Editorial (Should Chronic Kidney Disease be Considered as a Coronary Heart Disease Equivalent?)
Current Vascular Pharmacology Inflamm-ageing and senescence in gout: the tale of an old king’s disease.
Current Aging Science Thyroid Hormone Ligands and Metabolic Diseases
Current Pharmaceutical Design Impact of Sex on Office White Coat effect Tail: A Review
Current Pharmaceutical Design Cardiovascular Remodeling Induced by Passive Smoking
Inflammation & Allergy - Drug Targets (Discontinued) Hypertension and Concurrent Arrhythmias
Current Pharmaceutical Design Impact of the Fontan Operation on Organ Systems
Cardiovascular & Hematological Disorders-Drug Targets Current Concepts Underlying Benefits of Exercise Training in Congestive Heart Failure Patients
Current Cardiology Reviews Novel Classes of Dimer Antitumour Drug Candidates
Current Pharmaceutical Design Influence of Gender on C-Reactive Protein, Fibrinogen, and Erythrocyte Sedimentation Rate in Obstructive Sleep Apnea
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Glucose Blood Levels as a Therapeutic Target in Acute Ischaemic Stroke Setting
Current Topics in Medicinal Chemistry Dysregulation of SIRT-1 Signaling in Multiple Sclerosis and Neuroimmune Disorders: A Systematic Review of SIRTUIN Activators as Potential Immunomodulators and their Influences on other Dysfunctions
Endocrine, Metabolic & Immune Disorders - Drug Targets